ReviewDie Anaesthesiologie2026
[Packed red blood cells-Avoidable risks and complications].
Review in Die Anaesthesiologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Packed red blood cells (PRBC) are indispensable but high-risk therapeutic agents with a high quality of preparation but the safety of administration is compromised by avoidable errors. The physician's decision for a transfusion must consider both the inherent risk profile of the high-quality product and the safety of administration. Key problem areas in the clinical use of PRBCs include confusion of products and hemolytic transfusion reactions due to process or identification errors, undertransfusion resulting from logistical bottlenecks or misjudgement and overtransfusion due to the overreliance on hemoglobin concentrations as transfusion trigger and a lack of adherence to guidelines. The risk of PRBC overdosing, in particular, is currently underestimated. As a large proportion of adverse events are application-related and therefore potentially preventable, technical safeguards, digitalization, structured processes and consistent patient blood management are essential measures for increasing patient safety.
Indexed as
Identifiers
42024258What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.